-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The 2022 Annual Meeting of the European Society of Oncology (ESMO) was held
backgroundPatients with locally advanced BC have a poor
methodThis prospective, single-group, phase II trial included locally advanced urothelial BC (cT3/4 cN0/N+ cM0, suitable for radical cystectomy, not suitable for or denied neoadjuvant chemotherapy
Figure 1 Study design
outcomeA total of 33 patients were included in the study, and eventually 31 patients were included in the main study endpoint and efficacy analysis
Figure 2 Secondary study endpoint data
Of the 33 patients, 54.
conclusionThe RACE IT trial reached the primary endpoint and confirmed that neoadjuvant radio-immunotherapy prior to radical cystectomy is feasible and safe
References:
LR Reviewer: LR Executive: Wang Mumu
